Targeting Solid Tumors With BTK Inhibitors [PDF]
Frontiers in Cell and Developmental Biology, 2021 The repurposing of FDA-approved Bruton’s tyrosine kinase (BTK) inhibitors as therapeutic agents for solid tumors may offer renewed hope for chemotherapy-resistant cancer patients.
Fatih M. Uckun, Taracad Venkatachalam
doaj +3 more sources
Managing Waldenström's macroglobulinemia with BTK inhibitors. [PDF]
Leukemia, 2023 AbstractBruton’s tyrosine kinase (BTK) inhibition is one of the treatment standards for patients with relapsed/refractory Waldenström’s macroglobulinemia (WM) and for patients with WM who are unsuitable for immunochemotherapy (ICT). It offers deep and durable responses with a manageable safety profile that is generally favorable compared with ICT ...
Buske C +3 more
europepmc +5 more sources
Structure-based virtual screening and biological evaluation of novel small-molecule BTK inhibitors [PDF]
Journal of Enzyme Inhibition and Medicinal Chemistry, 2022 Bruton tyrosine kinase (BTK) is linked to multiple signalling pathways that regulate cellular survival, activation, and proliferation. A covalent BTK inhibitor has shown favourable outcomes for treating B cell malignant leukaemia.
Tony Eight Lin +10 more
doaj +2 more sources
The Development of BTK Inhibitors: A Five-Year Update [PDF]
Molecules, 2021 Bruton’s tyrosine kinase (BTK) represented, in the past ten years, an important target for the development of new therapeutic agents that could be useful for cancer and autoimmune disorders.
Bruno Tasso +3 more
doaj +2 more sources
BTK inhibitors: past, present, and future. [PDF]
Trends Pharmacol SciBruton's tyrosine kinase (BTK) inhibitors have revolutionized the treatment landscape for B cell lymphomas such as chronic lymphocytic leukemia (CLL). The first-in-class BTK inhibitor ibrutinib has recently been succeeded by covalent BTK inhibitors that are safer but still face challenges of resistance mutations.
Cool A, Nong T, Montoya S, Taylor J.
europepmc +3 more sources
BTK Inhibitors Impair Platelet-Mediated Antifungal Activity. [PDF]
Cells, 2022 In recent years, the introduction of new drugs targeting Bruton’s tyrosine kinase (BTK) has allowed dramatic improvement in the prognosis of patients with chronic lymphocytic leukemia (CLL) and other B-cell neoplasms. Although these small molecules were initially considered less immunosuppressive than chemoimmunotherapy, an increasing number of reports
Nasillo V +19 more
europepmc +4 more sources
Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia [PDF]
eLifeInhibition of Bruton’s tyrosine kinase (BTK) has proven to be highly effective in the treatment of B-cell malignancies such as chronic lymphocytic leukemia (CLL), autoimmune disorders, and multiple sclerosis. Since the approval of the first BTK inhibitor
Raji E Joseph +7 more
doaj +2 more sources
Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors. [PDF]
Blood Adv, 2023 Qi J +12 more
europepmc +3 more sources
Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma [PDF]
The Journal of Clinical Investigation, 2023 Bruton’s tyrosine kinase (BTK) is a proven target in mantle cell lymphoma (MCL), an aggressive subtype of non-Hodgkin lymphoma. However, resistance to BTK inhibitors is a major clinical challenge. We here report that MALT1 is one of the top overexpressed
Vivian Changying Jiang +20 more
doaj +2 more sources
Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases
Molecules, 2021 Bruton’s tyrosine kinase (BTK) plays a crucial role in B-cell receptor and Fc receptor signaling pathways. BTK is also involved in the regulation of Toll-like receptors and chemokine receptors.
Datong Zhang, He Gong, Fancui Meng
doaj +1 more source